These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Xiang J; Chen Y; Moyana T Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205 [TBL] [Abstract][Full Text] [Related]
4. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528 [TBL] [Abstract][Full Text] [Related]
5. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors. Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109 [TBL] [Abstract][Full Text] [Related]
6. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice. Zhang W; Yang H; Wang Z; Jim X Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920 [TBL] [Abstract][Full Text] [Related]
7. Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity. Xiang J; Munegowda MA; Deng Y Cancer Gene Ther; 2009 May; 16(5):430-8. PubMed ID: 19096444 [TBL] [Abstract][Full Text] [Related]
8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
9. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294 [TBL] [Abstract][Full Text] [Related]
10. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. Hao S; Yuan J; Xiang J J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150 [TBL] [Abstract][Full Text] [Related]
11. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
13. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide]. Zhang W; He L; Cao X Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Liu Y; Xia D; Li F; Zheng C; Xiang J Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183 [TBL] [Abstract][Full Text] [Related]
15. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927 [TBL] [Abstract][Full Text] [Related]
16. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
17. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751 [TBL] [Abstract][Full Text] [Related]